Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PRO_SELECT: combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective factor Xa inhibitors.
Liebeschuetz JW, Jones SD, Morgan PJ, Murray CW, Rimmer AD, Roscoe JM, Waszkowycz B, Welsh PM, Wylie WA, Young SC, Martin H, Mahler J, Brady L, Wilkinson K. Liebeschuetz JW, et al. Among authors: young sc. J Med Chem. 2002 Mar 14;45(6):1221-32. doi: 10.1021/jm010944e. J Med Chem. 2002. PMID: 11881991
A four component coupling strategy for the synthesis of D-phenylglycinamide-derived non-covalent factor Xa inhibitors.
Sheehan SM, Masters JJ, Wiley MR, Young SC, Liebeschuetz JW, Jones SD, Murray CW, Franciskovich JB, Engel DB, Weber WW, Marimuthu J, Kyle JA, Smallwood JK, Farmen MW, Smith GF. Sheehan SM, et al. Among authors: young sc. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2255-9. doi: 10.1016/s0960-894x(03)00462-1. Bioorg Med Chem Lett. 2003. PMID: 12824013
Investigation of the terminal P4 domain in a series of D-phenylglycinamide-based factor Xa inhibitors.
Franciskovich JB, Masters JJ, Weber WW, Klimkowski VJ, Chouinard M, Sipes PR, Johnson LM, Snyder DW, Chastain MK, Craft TJ, Towner RD, Gifford-Moore DS, Froelich LL, Smallwood JK, Foster RS, Smith GF, Liebeschuetz JW, Murray CW, Young SC. Franciskovich JB, et al. Among authors: young sc. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6910-3. doi: 10.1016/j.bmcl.2007.09.105. Epub 2007 Oct 24. Bioorg Med Chem Lett. 2007. PMID: 17976987
Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.
Charrier JD, Durrant SJ, Golec JM, Kay DP, Knegtel RM, MacCormick S, Mortimore M, O'Donnell ME, Pinder JL, Reaper PM, Rutherford AP, Wang PS, Young SC, Pollard JR. Charrier JD, et al. Among authors: young sc. J Med Chem. 2011 Apr 14;54(7):2320-30. doi: 10.1021/jm101488z. Epub 2011 Mar 17. J Med Chem. 2011. PMID: 21413798
Structure-based optimization of aminopyridines as PKCθ inhibitors.
Jimenez JM, Davis C, Boyall D, Fraysse D, Knegtel R, Settimo L, Young S, Bolton C, Chiu P, Curnock A, Rasmussen R, Tanner A, Ager I. Jimenez JM, et al. Bioorg Med Chem Lett. 2012 Jul 15;22(14):4645-9. doi: 10.1016/j.bmcl.2012.05.114. Epub 2012 Jun 6. Bioorg Med Chem Lett. 2012. PMID: 22738630
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Guo Y, Liu Y, Hu N, Yu D, Zhou C, Shi G, Zhang B, Wei M, Liu J, Luo L, Tang Z, Song H, Guo Y, Liu X, Su D, Zhang S, Song X, Zhou X, Hong Y, Chen S, Cheng Z, Young S, Wei Q, Wang H, Wang Q, Lv L, Wang F, Xu H, Sun H, Xing H, Li N, Zhang W, Wang Z, Liu G, Sun Z, Zhou D, Li W, Liu L, Wang L, Wang Z. Guo Y, et al. J Med Chem. 2019 Sep 12;62(17):7923-7940. doi: 10.1021/acs.jmedchem.9b00687. Epub 2019 Aug 19. J Med Chem. 2019. PMID: 31381333
84 results